ICICI Prudential Mutual Fund has announced an acquisition of 7,12,884 equity shares of Dr. Reddy’s Laboratories Ltd. This transaction, which occurred on August 12, 2026, has pushed the Fund’s total shareholding to exceed 5% of the paid-up capital of the company. The acquisition is stated to be from an investment perspective, without the intention of seeking controlling interest.
ICICI Prudential Mutual Fund Increases Stake in Dr. Reddy’s Laboratories
ICICI Prudential Mutual Fund, through its various schemes and investment strategies, has significantly increased its stake in Dr. Reddy’s Laboratories Ltd. On August 12, 2026, the fund acquired an additional 7,12,884 shares of the pharmaceutical company. This move brings ICICI Prudential Mutual Fund’s total shareholding beyond the 5% threshold of Dr. Reddy’s Laboratories’ paid-up capital.
Investment Strategy and Disclosure
The acquisition has been characterized by ICICI Prudential Mutual Fund as being purely from an investment perspective, with no objective of gaining controlling interest in Dr. Reddy’s Laboratories. As per the requirements of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, a formal disclosure has been made regarding this development.
Prior to this acquisition, ICICI Prudential Mutual Fund held 4,13,32,755 shares, representing 4.952% of the total voting capital. Following the purchase, the total holding stands at 4,20,45,639 shares, equating to 5.037% of the voting capital. This increased shareholding necessitates transparency and adherence to regulatory disclosure norms.
Source: BSE
